dual gip and glp-1 receptor agonist Targeting GLP-1, & GCG in Obesity Type 2 Diabetes Research The Emerging Role of Dual
Description
Grenon SM, Vittinghoff E, Owens CD, Conte MS, Whooley M, Cohen BE
Revelations about carotid body function through its pathological role in resistant hypertension
Lingvay I, Perez MF, Garcia-Hernandez P, et al
Also in development is CagriSema , a new type of medication for type 2 diabetes and weight management that combines semaglutide and cagrilintide
Clinical implication The potential ocular complications associated with GLP-1 RAs need careful clinical consideration
Patients should be educated on gastrointestinal side effects at treatment initiation
